Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

872272

	registered interest
	date	26/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Acute Lymphoblastic Leukaemia: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the availability of treatments for patients diagnosed with Refractory B-cell Acute Lymphoblastic Leukaemia.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	134186
	answer	answer is ministerial correction date of answer 03/04/2018 answer text <p>The following treatments are routinely available, having undergone Technical Appraisals by the National Institute for Health and Care Excellence (NICE). They were previously accessible through the Cancer Drugs Fund.</p><p> </p><p>- Blinatumomab for relapsed refractory (r/r) Philadelphia negative acute lymphoblastic leukaemia (ALL); and</p><p>- Ponatinib for Philadelphia positive ALL in patients in whom imatinib is not clinically appropriate (which might cover some r/r).</p><p> </p><p>The following treatments are currently under consideration by NICE:</p><p> </p><p>- CAR-T (Tisagenlecleucel-T and also Axicabtagene ciloleucel) for previously treated B-cell ALL in people aged 3 to 21 at initial diagnosis;</p><p>- Inotuzumab ozogamicin for treating r/r ALL; and</p><p>- Blinatumomab in other extended indications in ALL.</p><p> </p><p>Finally, the following treatments are currently accessible through the Cancer Drugs Fund.</p><p> </p><p>- Clofarabine for treating ALL in children after two therapies; and</p><p>- Nelarabine for treating ALL after two therapies.</p><p> </p><p>Information on the number and proportion of patients with refractory B-cell Acute Lymphoblastic Leukaemia who have been unable to access treatments for that condition is not held centrally.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 134187 question first answered 03/04/2018 13:25:08 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

872273

	registered interest
	date	26/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Acute Lymphoblastic Leukaemia: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of patients with Refractory B-cell Acute Lymphoblastic Leukaemia have been unable to access treatments for that condition.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	134187
	answer	answer is ministerial correction date of answer 03/04/2018 answer text <p>The following treatments are routinely available, having undergone Technical Appraisals by the National Institute for Health and Care Excellence (NICE). They were previously accessible through the Cancer Drugs Fund.</p><p> </p><p>- Blinatumomab for relapsed refractory (r/r) Philadelphia negative acute lymphoblastic leukaemia (ALL); and</p><p>- Ponatinib for Philadelphia positive ALL in patients in whom imatinib is not clinically appropriate (which might cover some r/r).</p><p> </p><p>The following treatments are currently under consideration by NICE:</p><p> </p><p>- CAR-T (Tisagenlecleucel-T and also Axicabtagene ciloleucel) for previously treated B-cell ALL in people aged 3 to 21 at initial diagnosis;</p><p>- Inotuzumab ozogamicin for treating r/r ALL; and</p><p>- Blinatumomab in other extended indications in ALL.</p><p> </p><p>Finally, the following treatments are currently accessible through the Cancer Drugs Fund.</p><p> </p><p>- Clofarabine for treating ALL in children after two therapies; and</p><p>- Nelarabine for treating ALL after two therapies.</p><p> </p><p>Information on the number and proportion of patients with refractory B-cell Acute Lymphoblastic Leukaemia who have been unable to access treatments for that condition is not held centrally.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 134186 question first answered 03/04/2018 13:25:08 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

174759

	registered interest
	date	20/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Bile Duct Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what research his Department has commissioned into cholangiocarcinoma.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	221396
	answer	answer is ministerial correction date of answer 27/01/2015 answer text <p>The Department has not commissioned any research relating specifically to cholangiocarcinoma. The National Institute for Health Research Imperial Biomedical Research Centre has a £3.6 million gastroenterology and hepatology research theme (2012-17). This includes research on cholangiocarcinoma biomarkers and imaging.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 27/01/2015 12:35:01 answering member 4020 label Biography information for George Freeman
	tabling member	3960 label Biography information for Henry Smith

528906

	registered interest
	date	27/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Blood Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the implications for his policies of the findings of the National Cancer Patient Experience Survey 2015 on the proportion of blood cancer patients who visited their GP more than twice before being referred to secondary care for diagnosis; and what support and guidance his Department has provided to GPs to enable them to identify the symptoms of blood cancer.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	41284
	answer	answer is ministerial correction date of answer 05/07/2016 answer text <p>It is important that people with cancer have the best possible experience throughout their cancer pathway and are treated with dignity and respect.</p><p> </p><p>The independent Cancer Taskforce published its report <em>Achieving World-Class Cancer Outcomes – A Strategy for England 2015-2020</em> in July 2015, and identified a key priority of establishing patient experience as being on a par with clinical effectiveness and safety. In May 2016 the National Cancer Transformation Board published <em>Achieving World-Class Cancer Outcomes:</em> <em>Taking the Strategy Forward</em> outlining the detailed steps being taken to make this a reality.</p><p> </p><p>In September 2015, the Government announced that by 2020, the 280,000 people diagnosed with cancer every year will benefit from a tailored recovery package. The packages will be individually designed to help each person, including those with blood cancer, live well beyond cancer. In April 2016 NHS England published guidance for commissioners on commissioning and implementing the recovery package effectively.</p><p> </p><p>In order to continue to support general practitioners (GPs) to identify patients whose symptoms may indicate cancer and urgently refer them as appropriate, the National Institute for Health and Care Excellence (NICE) published an updated suspected cancer referral guideline in June 2015. The guideline includes new recommendations for haematological cancers. NICE noted that more lives could be saved each year in England if GPs followed the new guideline, which encourages GPs to think of cancer sooner and lower the referral threshold. Following publication of the updated guideline, the Royal College of GPs (RCGP) has worked in collaboration with Cancer Research UK (CRUK) on a programme of regional update events for GPs to promote the new guideline. RCGP and CRUK have also worked to develop three summary referral guidelines for GPs to enable them to adopt the guideline. These are available at:</p><p> </p><p><a href="http://www.cancerresearchuk.org/health-professional/learning-and-development-tools/nice-cancer-referral-guidelines" target="_blank">www.cancerresearchuk.org/health-professional/learning-and-development-tools/nice-cancer-referral-guidelines</a></p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 41285 41329 question first answered 05/07/2016 15:11:22 answering member 3918 label Biography information for Jane Ellison
	tabling member	3960 label Biography information for Henry Smith

528908

	registered interest
	date	27/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Blood Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the implications for his policies of the findings of the National Cancer Patient Experience Survey 2015 on the proportion of blood cancer patients that understood the explanation given to them at diagnosis; and if he will take steps to increase support for such patients at the point of diagnosis.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	41285
	answer	answer is ministerial correction date of answer 05/07/2016 answer text <p>It is important that people with cancer have the best possible experience throughout their cancer pathway and are treated with dignity and respect.</p><p> </p><p>The independent Cancer Taskforce published its report <em>Achieving World-Class Cancer Outcomes – A Strategy for England 2015-2020</em> in July 2015, and identified a key priority of establishing patient experience as being on a par with clinical effectiveness and safety. In May 2016 the National Cancer Transformation Board published <em>Achieving World-Class Cancer Outcomes:</em> <em>Taking the Strategy Forward</em> outlining the detailed steps being taken to make this a reality.</p><p> </p><p>In September 2015, the Government announced that by 2020, the 280,000 people diagnosed with cancer every year will benefit from a tailored recovery package. The packages will be individually designed to help each person, including those with blood cancer, live well beyond cancer. In April 2016 NHS England published guidance for commissioners on commissioning and implementing the recovery package effectively.</p><p> </p><p>In order to continue to support general practitioners (GPs) to identify patients whose symptoms may indicate cancer and urgently refer them as appropriate, the National Institute for Health and Care Excellence (NICE) published an updated suspected cancer referral guideline in June 2015. The guideline includes new recommendations for haematological cancers. NICE noted that more lives could be saved each year in England if GPs followed the new guideline, which encourages GPs to think of cancer sooner and lower the referral threshold. Following publication of the updated guideline, the Royal College of GPs (RCGP) has worked in collaboration with Cancer Research UK (CRUK) on a programme of regional update events for GPs to promote the new guideline. RCGP and CRUK have also worked to develop three summary referral guidelines for GPs to enable them to adopt the guideline. These are available at:</p><p> </p><p><a href="http://www.cancerresearchuk.org/health-professional/learning-and-development-tools/nice-cancer-referral-guidelines" target="_blank">www.cancerresearchuk.org/health-professional/learning-and-development-tools/nice-cancer-referral-guidelines</a></p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 41284 41329 question first answered 05/07/2016 15:11:22 answering member 3918 label Biography information for Jane Ellison
	tabling member	3960 label Biography information for Henry Smith

528917

	registered interest
	date	27/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Blood Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he has taken to adapt the cancer recovery package and investigate new models of care for blood cancer patients who are (a) given treatment and (b) put on a watch and wait regime after diagnosis.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	41329
	answer	answer is ministerial correction date of answer 05/07/2016 answer text <p>It is important that people with cancer have the best possible experience throughout their cancer pathway and are treated with dignity and respect.</p><p> </p><p>The independent Cancer Taskforce published its report <em>Achieving World-Class Cancer Outcomes – A Strategy for England 2015-2020</em> in July 2015, and identified a key priority of establishing patient experience as being on a par with clinical effectiveness and safety. In May 2016 the National Cancer Transformation Board published <em>Achieving World-Class Cancer Outcomes:</em> <em>Taking the Strategy Forward</em> outlining the detailed steps being taken to make this a reality.</p><p> </p><p>In September 2015, the Government announced that by 2020, the 280,000 people diagnosed with cancer every year will benefit from a tailored recovery package. The packages will be individually designed to help each person, including those with blood cancer, live well beyond cancer. In April 2016 NHS England published guidance for commissioners on commissioning and implementing the recovery package effectively.</p><p> </p><p>In order to continue to support general practitioners (GPs) to identify patients whose symptoms may indicate cancer and urgently refer them as appropriate, the National Institute for Health and Care Excellence (NICE) published an updated suspected cancer referral guideline in June 2015. The guideline includes new recommendations for haematological cancers. NICE noted that more lives could be saved each year in England if GPs followed the new guideline, which encourages GPs to think of cancer sooner and lower the referral threshold. Following publication of the updated guideline, the Royal College of GPs (RCGP) has worked in collaboration with Cancer Research UK (CRUK) on a programme of regional update events for GPs to promote the new guideline. RCGP and CRUK have also worked to develop three summary referral guidelines for GPs to enable them to adopt the guideline. These are available at:</p><p> </p><p><a href="http://www.cancerresearchuk.org/health-professional/learning-and-development-tools/nice-cancer-referral-guidelines" target="_blank">www.cancerresearchuk.org/health-professional/learning-and-development-tools/nice-cancer-referral-guidelines</a></p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 41284 41285 question first answered 05/07/2016 15:11:22 answering member 3918 label Biography information for Jane Ellison
	tabling member	3960 label Biography information for Henry Smith

836016

	registered interest
	date	02/02/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many emergency presentations there were of blood cancer; what proportion of those presentations were of all diagnoses of blood cancer; and what proportion those were of the total of all emergency presentations of cancer in each of the last five years for which figures are available.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	126371
	answer	answer is ministerial correction date of answer 08/02/2018 answer text <p>In 2015, the latest year for which data are available, the percentage of patients diagnosed after an emergency presentation in England for all blood cancers was 28% (7,626 of 26,869).</p><p> </p><p>There has been a fall in the percentage diagnosed through this emergency presentation route over the last 10 years for some of these cancers: chronic lymphocytic leukaemia (26% in 2006 down to 13% in 2015), multiple myeloma (37% down to 31%), and other haematological malignancies (37% down to 25%). The proportion over time in the other groups remained relatively stable.</p><p> </p><p>As a proportion of all emergency diagnoses, the proportion of blood cancers diagnosed as an emergency was 12% in 2011 and 13% in each of 2012-2015.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 126372 question first answered 08/02/2018 14:30:04 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

836017

	registered interest
	date	02/02/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of trends in the instances of blood cancer being diagnosed after an emergency admission; and if he will make a statement.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	126372
	answer	answer is ministerial correction date of answer 08/02/2018 answer text <p>In 2015, the latest year for which data are available, the percentage of patients diagnosed after an emergency presentation in England for all blood cancers was 28% (7,626 of 26,869).</p><p> </p><p>There has been a fall in the percentage diagnosed through this emergency presentation route over the last 10 years for some of these cancers: chronic lymphocytic leukaemia (26% in 2006 down to 13% in 2015), multiple myeloma (37% down to 31%), and other haematological malignancies (37% down to 25%). The proportion over time in the other groups remained relatively stable.</p><p> </p><p>As a proportion of all emergency diagnoses, the proportion of blood cancers diagnosed as an emergency was 12% in 2011 and 13% in each of 2012-2015.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 126371 question first answered 08/02/2018 14:30:04 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

836018

	registered interest
	date	02/02/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether diagnostic centres established as a result of the Cancer Strategy for England take specific account of blood cancer; and if he will make a statement.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	126373
	answer	answer is ministerial correction date of answer 08/02/2018 answer text <p>The wave two of the Accelerate, Coordination and Evaluation (ACE) programme is testing a new multi-disciplinary diagnostic centre approach to diagnosing patients with vague or unclear but concerning symptoms, often characteristic of hard to diagnose cancers like blood cancers. This approach aims to ensure that patients can receive a suite of tests, reducing the risk that patients receive multiple different referrals for the same problem. The ACE programme has established ten pilot Rapid Diagnostic Assessment Centres across five areas of the country.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 08/02/2018 15:33:52 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

836019

	registered interest
	date	02/02/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what proportion of people diagnosed with blood cancer have had access to a clinical nurse specialist in each of the last three years; and if he will make a statement.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	126374
	answer	answer is ministerial correction date of answer 08/02/2018 answer text <p>NHS England does not collect this information centrally.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 08/02/2018 14:39:50 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith